CSL Eyes Pediatric Segment as Key to Stabilizing Flu-Vaccine Revenue -- Market Talk

Dow Jones

08/19

0256 GMT - When asked on an analyst call why CSL thinks that its seasonal flu-vaccine revenues will stabilize, CEO Paul McKenzie replied that the company has been investing in the pediatric segment. He was speaking after the company announced that it would spin off its flu-vaccine business Seqirus and list it separately in Australia. A couple of years ago, CSL's share of the pediatric segment was zero, but now the company is expecting to soon achieve about 20% share, he said, adding that most of the vaccine fatigue is in the 18-64-year-old category. The stock is down 13% following annual earnings and the spinoff plan. (mike.cherney@wsj.com)

(END) Dow Jones Newswires

August 18, 2025 22:56 ET (02:56 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2560563121"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560563121\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560563121?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 10:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560563121","market":"sh","top_or_hot":-1,"title":"CSL Eyes Pediatric Segment as Key to Stabilizing Flu-Vaccine Revenue -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0256 GMT - When asked on an analyst call why CSL thinks that its seasonal flu-vaccine revenues will stabilize, CEO Paul McKenzie replied that the company has been investing in the pediatric segment. He was speaking after the company announced that it would spin off its flu-vaccine business Seqirus and list it separately in Australia. A couple of years ago, CSL's share of the pediatric segment was zero, but now the company is expecting to soon achieve about 20% share, he said, adding that most of the vaccine fatigue is in the 18-64-year-old category. The stock is down 13% following annual earnings and the spinoff plan. (mike.cherney@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 18, 2025 22:56 ET (02:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Eyes Pediatric Segment as Key to Stabilizing Flu-Vaccine Revenue -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Eyes Pediatric Segment as Key to Stabilizing Flu-Vaccine Revenue -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-19 10:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0256 GMT - When asked on an analyst call why CSL thinks that its seasonal flu-vaccine revenues will stabilize, CEO Paul McKenzie replied that the company has been investing in the pediatric segment. He was speaking after the company announced that it would spin off its flu-vaccine business Seqirus and list it separately in Australia. A couple of years ago, CSL's share of the pediatric segment was zero, but now the company is expecting to soon achieve about 20% share, he said, adding that most of the vaccine fatigue is in the 18-64-year-old category. The stock is down 13% following annual earnings and the spinoff plan. (mike.cherney@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 18, 2025 22:56 ET (02:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡莱尔伙伴","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2560563121","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560563121","pubTimestamp":1755572160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0256 GMT - When asked on an analyst call why CSL thinks that its seasonal flu-vaccine revenues will stabilize, CEO Paul McKenzie replied that the company has been investing in the pediatric segment. He was speaking after the company announced that it would spin off its flu-vaccine business Seqirus and list it separately in Australia. A couple of years ago, CSL's share of the pediatric segment was zero, but now the company is expecting to soon achieve about 20% share, he said, adding that most of the vaccine fatigue is in the 18-64-year-old category. The stock is down 13% following annual earnings and the spinoff plan. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴","CSL.AU":"CSL LIMITED"},"translate_title":"CSL将儿科领域视为稳定流感疫苗收入的关键——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9,"CSL":1},"content_text":"0256 GMT - When asked on an analyst call why CSL thinks that its seasonal flu-vaccine revenues will stabilize, CEO Paul McKenzie replied that the company has been investing in the pediatric segment. He was speaking after the company announced that it would spin off its flu-vaccine business Seqirus and list it separately in Australia. A couple of years ago, CSL's share of the pediatric segment was zero, but now the company is expecting to soon achieve about 20% share, he said, adding that most of the vaccine fatigue is in the 18-64-year-old category. The stock is down 13% following annual earnings and the spinoff plan. (mike.cherney@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 18, 2025 22:56 ET (02:56 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}